[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657910":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":11,"studyPopulation":11,"armGroups":36,"interventions":55,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":71,"collaborators":11,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":11,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":11,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":11,"overallStatus":92,"whyStopped":11,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":98,"leadSponsor":100,"locationsCount":11},{"fullName":5,"class":6},"Guangzhou JOYO Pharma Co., Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Percent change from baseline in EASI score at Week 8",null,"Baseline to Week 8",[14,17,20,22,24],{"measure":15,"description":11,"timeFrame":16},"Proportion of participants achieving EASI 50\u002F75\u002F90 at Weeks 1, 2, 4, and 8","Weeks 1, 2, 4, 8",{"measure":18,"description":11,"timeFrame":19},"Percent change from baseline in EASI score at Weeks 1, 2, and 4","Weeks 1, 2, 4",{"measure":21,"description":11,"timeFrame":16},"Proportion of participants with vIGA-AD response at Weeks 1, 2, 4, 8",{"measure":23,"description":11,"timeFrame":16},"Proportion of participants with vIGA-AD score 0\u002F1 at Weeks 1, 2, 4, 8",{"measure":25,"description":11,"timeFrame":16},"Proportion of participants with ≥2-point improvement in vIGA-AD from baseline at Weeks 1, 2, 4, 8",{"allocation":27,"interventionModel":28,"interventionModelDescription":11,"primaryPurpose":29,"observationalModel":11,"timePerspective":11,"maskingInfo":30},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":31,"maskingDescription":11,"whoMasked":32},"TRIPLE",[33,34,35],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR",[37,42,46,50],{"label":38,"type":39,"description":11,"interventionNames":40},"4% JYP0066 topical cream - applied twice daily (BID) to affected skin areas for 8 weeks","EXPERIMENTAL",[41],"Drug: JYP0066 4% topical cream",{"label":43,"type":39,"description":11,"interventionNames":44},"3% JYP0066 topical cream - applied twice daily (BID) for 8 weeks",[45],"Drug: 3% JYP0066 topical cream",{"label":47,"type":39,"description":11,"interventionNames":48},"2% JYP0066 topical cream - applied twice daily (BID) for 8 weeks",[49],"Drug: 2% JYP0066 topical cream",{"label":51,"type":52,"description":11,"interventionNames":53},"Matching placebo cream (vehicle, no active ingredient) - applied twice daily (BID) for 8 weeks","PLACEBO_COMPARATOR",[54],"Drug: Matching placebo cream (vehicle, no active ingredient)",[56,61,65,68],{"type":57,"name":58,"description":59,"armGroupLabels":60,"otherNames":11},"DRUG","JYP0066 4% topical cream","applied twice daily (BID) to affected skin areas for 8 weeks",[38],{"type":57,"name":62,"description":63,"armGroupLabels":64,"otherNames":11},"3% JYP0066 topical cream","applied twice daily (BID) for 8 weeks",[43],{"type":57,"name":66,"description":63,"armGroupLabels":67,"otherNames":11},"2% JYP0066 topical cream",[47],{"type":57,"name":69,"description":63,"armGroupLabels":70,"otherNames":11},"Matching placebo cream (vehicle, no active ingredient)",[51],{"type":72,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100657910","phase-2-phase-ii-trial-of-jyp0066-cream-in-mild-to-moderate-atopic-dermatitis-100657910",false,"NCT07843290","A Study of JYP0066 Cream in Mild-to-Moderate Atopic Dermatitis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of JYP0066 Topical Cream in Adolescents and Adults With Mild-to-Moderate Atopic Dermatitis","Inclusion Criteria:\n\n* Participant is ≥12 and ≤75 years of age at the time of signing informed consent; male or female.\n\nNote: Participants who are ≥12 and \\\u003C18 years of age at screening and baseline will be classified as adolescents throughout the study.\n\nBody weight ≥40 kg. Meets Williams diagnostic criteria for atopic dermatitis (AD) at screening and baseline, with AD onset at least 6 months before screening.\n\nWilliams criteria - Major criterion: itchy skin. Minor criteria: (a) history of flexural dermatitis (elbow\u002Fantecubital, popliteal, anterior ankle, neck; in children \\\u003C10 y, cheek rash); (b) history of asthma or allergic rhinitis (or atopic disease in first-degree relatives for children \\\u003C4 y); (c) generalized dry skin in recent years; (d) flexural eczema (in children \\\u003C4 y: cheek\u002Fforehead\u002Fextensor eczema); (e) onset before age 2 (for patients ≥4 y). Diagnosis = major criterion + ≥3 minor criteria.\n\nvIGA-AD score of 2 (mild) or 3 (moderate) at both screening and baseline. Total AD lesion area of 3%-20% body surface area (BSA) at screening and baseline.\n\nNote: Lesions on scalp, face, and genital area are excluded from BSA calculation at screening and baseline.\n\nFemales of childbearing potential must have a negative serum pregnancy test at screening. All participants of childbearing potential (and their partners) must agree to use highly effective contraception from informed consent through 1 month after last study drug administration and must not donate sperm\u002Fova during this period.\n\nNote: Applies also to post-menarchal female adolescents and post-semenarche male adolescents.\n\nAdults: able to understand the purpose and procedures of the study, voluntarily provide written informed consent, and comply with visits\u002Frequirements. Adolescents: participant and parent\u002Flegal guardian (as applicable) voluntarily provide written informed consent\u002Fassent and can communicate with investigator and attend scheduled visits.\n\nExclusion Criteria:\n\n* Presence of other skin diseases or skin infections that may interfere with AD assessment at screening\u002Fbaseline, or large tattoos, birthmarks, or scars over AD lesions at screening\u002Fbaseline.\n\nUnstable AD, or continuously requiring potent topical corticosteroids to control signs\u002Fsymptoms.\n\nAD lesions located only or mainly on hands, feet, scalp, face, or genitals with no history of classic flexural involvement.\n\nKnown\u002Fsuspected allergy to any component of study cream or its vehicle, or moderate-to-severe allergic disease at IC signing (e.g., food\u002Fdrug\u002Fdetergent allergy; AD-related allergy allowed); or history of moderate-to-severe allergic disease.\n\nUse of any of the following prior to study drug:\n\nAny systemic or topical JAK inhibitor before study entry; Biologics affecting AD (e.g., anti-IL-4, IL-5, IL-12\u002F23, IL-13, IL-31, CD20, TNF-α, IgE) within 12 weeks or 5 half-lives (whichever longer) before study drug; Systemic immunosuppressants\u002Fimmunomodulators (cyclosporine, MTX, azathioprine, MMF), oral\u002Fsystemic corticosteroids, PDE4 inhibitors within 4 weeks or 5 half-lives (whichever longer); Systemic herbal\u002FChinese medicine for AD or other autoimmune-inflammatory diseases within 4 weeks; Phototherapy (NBUVB, UVB, UVA1, PUVA), tanning bed, or other light-emitting device within 4 weeks; Any topical AD treatment (except non-medicated emollient) or antihistamines within 1 week (stable-dose antihistamine before screening allowed); Participation in another clinical trial within 4 weeks or 5 half-lives of investigational product (whichever longer); Any vaccination within 4 weeks, BCG within 1 year, or planned live\u002Fattenuated vaccine during study; Long-acting anticoagulants (warfarin, dabigatran) within 4 weeks or need for continuous anticoagulation (aspirin ≤100 mg\u002Fday allowed); Strong CYP3A4 inhibitors\u002Finducers (rifampin, fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole, nefazodone) within 2 weeks or 5 half-lives; Allergen-specific immunotherapy within 6 months. Major surgical procedure within 12 weeks before screening. Serious infectious disease within 6 months; history of zoster or disseminated zoster; any infection requiring antibiotics within 2 weeks before screening; or active acute\u002Fchronic\u002Flocal infection at screening; or infection judged by investigator likely to worsen with participation.\n\nActive tuberculosis, untreated latent TB, or incompletely cured TB (by history, symptoms, labs, IGRA, imaging).\n\nConditions negatively affecting immune response (e.g., organ transplant), or known immunodeficiency (acquired, genetic, or drug-induced).\n\nNYHA Class III\u002FIV heart failure; unstable angina; stroke\u002FTIA; MI; CABG\u002FPCI history; uncontrolled hypertension (SBP \\>160 or DBP \\>100 mmHg); hypotension (SBP \\\u003C90 or DBP \\\u003C60); clinically significant electrolyte disorder; or other unstable disease affecting safety.\n\nHistory of thromboembolic event (DVT, pulmonary embolism, CVA) or known genetic hypercoagulable state.\n\nClinically relevant severe pulmonary disease (e.g., pulmonary hypertension, acute COPD exacerbation, pneumothorax).\n\nSevere GI disease (peptic ulcer, obstruction) or condition affecting drug absorption (e.g., gastrectomy).\n\nSevere hematologic disease (moderate\u002Fsevere anemia, proliferative bone marrow disease, thrombocytopenia, hemoglobinopathy), severe coagulation abnormality, or high thrombotic risk.\n\nMalignant tumor or lymphoproliferative disease within past 10 years, except adequately treated non-melanoma skin cancer or cervical intraepithelial neoplasia.\n\nScreening 12-lead ECG with prolonged QTcF (\\>450 ms male, \\>470 ms female), family history of long QT, or chronic use of QT-prolonging drugs.","ALL","12 Years","75 Years",{"count":84,"type":85},160,"ESTIMATED","INTERVENTIONAL",[88],"PHASE2","This is a Phase 2 research study testing an investigational topical cream called JYP0066 for the treatment of mild-to-moderate atopic dermatitis (eczema) in teenagers (12-17 years old) and adults. The study will check whether JYP0066 cream can reduce eczema signs and symptoms such as redness, itching, dryness, and skin thickening, and whether it is safe and well tolerated.\n\nParticipants will be randomly assigned to one of four groups: they will apply either 4%, 3%, or 2% JYP0066 cream, or a matching placebo cream, to eczema-affected skin twice a day for 8 weeks. All creams will look the same. This helps the study compare which concentration works best and how safe each one is.",[91],"Atopic Dermatitis (AD)","NOT_YET_RECRUITING","2026-09-27",{"date":95,"type":96},"2026-09-30","ACTUAL",{"date":95,"type":85},{"date":99,"type":85},"2027-12-31",{"name":5,"class":6}]